DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21176/S-034, S-038
NDA 22362/S-015, S-017, S-018

SUPPLEMENT APPROVAL

Daiichi Sankyo, Inc.
Attention: Zoya Borodanski
Director, Regulatory Affairs
399 Thornall Street
Edison, NJ 08837

Dear Ms. Borodanski:

Please refer to the following Supplemental New Drug Applications (sNDAs) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Welchol (colesevelam) Tablets [NDA 21176] and Oral Suspension [NDA 22362]:

NDA 21176/S-034
This supplement, submitted August 31, 2012, revises the ADVERSE REACTIONS (6.1 Clinical Studies Experience) and USE IN SPECIFIC POPULATIONS (8.5 Geriatric Use, *Type 2 Diabetes Mellitus* and 8.7 Renal Impairment) sections of the package insert to include results from study WEL-A-U305 entitled *A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Welchol as Monotherapy for Type 2 Diabetes Mellitus*. This study was conducted in response to a postmarketing commitment (PMC) contained in the January 18, 2008, approval letter for Supplement -017.

NDA 21176/S-038
This supplement, submitted May 23, 2013, revises the DESCRIPTION and WARNINGS AND PRECAUTIONS sections of the shared package insert to include the correct amount of phenylalanine in the Oral Suspension formulation (13.5 mg and 27 mg for the 1.875 and 3.75 gram pouches, respectively).

NDA 22362/S-015
This supplement, submitted October 3, 2012, proposes a new non-child-resistant packaging (b) (4)

NDA 22362/S-017
This supplement, submitted May 23, 2013, revises the DESCRIPTION and WARNINGS AND PRECAUTIONS sections of the shared package insert to include the correct amount of

phenylalanine in the Oral Suspension formulation. This supplement also revises the carton and container labels.

NDA 22362/S-018
This supplement, submitted June 26, 2013, revises the ADVERSE REACTIONS (6.1 Clinical Studies Experience) and USE IN SPECIFIC POPULATIONS (8.5 Geriatric Use, *Type 2 Diabetes Mellitus* and 8.7 Renal Impairment) sections of the shared package insert to include the results from study WEL-A-U305 (see NDA 21176/S-034 above).

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

Regarding the revisions to the package insert in NDA 21176/ S-034, we note the agreement that you will combine the adverse reactions described in subsection 6.1 (Clinical Studies Experience) for the monotherapy and add-on combination diabetes studies. You also agreed to combine monotherapy and add-on combination study information in the Geriatric Use (8.5) and Renal Impairment (8.7) subsections of section 8 USE IN SPECIFIC POPULATIONS. These revisions will be made during labeling negotiations for your pending supplement, NDA 22362/S-037.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the enclosed carton and immediate container as soon as they are available, but no more than 30 days after they are printed.

Please submit these labels electronically according to the guidance for industry titled "Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)." Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 22362/S-015, S-017**." Approval of this submission by FDA is not required before the labeling is used.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kati Johnson, Regulatory Project Manager, at (301) 796-1234.

Sincerely,

{See appended electronic signature page}

Eric Colman, MD
Deputy Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURES:

Content of Labeling: Package Insert
Carton and Container Labeling:

- 1.875 gram trade pouch (non-child-resistant)
- 1.875 gram trade carton (non-child-resistant) (contains 60 pouches)
- 3.75 gram sample pouch (non-child-resistant)
- 3.75 gram sample carton (contains 3 pouches)
- 3.75 gram trade pouch (non-child-resistant)
- 3.75 gram trade carton (non-child-resistant)(contains 30 pouches)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC C COLMAN
06/28/2013